IL151089A0 - Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract - Google Patents

Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Info

Publication number
IL151089A0
IL151089A0 IL15108901A IL15108901A IL151089A0 IL 151089 A0 IL151089 A0 IL 151089A0 IL 15108901 A IL15108901 A IL 15108901A IL 15108901 A IL15108901 A IL 15108901A IL 151089 A0 IL151089 A0 IL 151089A0
Authority
IL
Israel
Prior art keywords
gastro
treatment
inflammatory diseases
binding molecules
intestinal tract
Prior art date
Application number
IL15108901A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL151089A0 publication Critical patent/IL151089A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15108901A 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract IL151089A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (1)

Publication Number Publication Date
IL151089A0 true IL151089A0 (en) 2003-04-10

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15108901A IL151089A0 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Country Status (18)

Country Link
US (2) US20050226872A1 (sk)
EP (1) EP1268553A1 (sk)
JP (1) JP2003528890A (sk)
KR (2) KR20080079702A (sk)
CN (1) CN1416432A (sk)
AU (2) AU4651601A (sk)
BR (1) BR0109549A (sk)
CA (1) CA2401249A1 (sk)
GB (1) GB0007911D0 (sk)
HU (1) HUP0301846A3 (sk)
IL (1) IL151089A0 (sk)
NO (1) NO20024579L (sk)
NZ (1) NZ520547A (sk)
PL (1) PL357014A1 (sk)
RU (1) RU2286797C2 (sk)
SK (1) SK13892002A3 (sk)
WO (1) WO2001072845A1 (sk)
ZA (1) ZA200207736B (sk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1379557E (pt) * 2001-04-06 2008-12-29 Univ Bristol Utilização de moléculas de ligação a cd25 em doentes resistentes a esteróides
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2 DIAGNOSTIC METHODS
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
CN102439452B (zh) * 2009-01-15 2015-04-15 美国控股实验室公司 通过测量her-2表达确定患者应答的方法
SG10201408392PA (en) 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
KR102493433B1 (ko) * 2011-05-02 2023-01-27 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
ES2291040T3 (es) * 1998-07-27 2008-02-16 Novartis Ag Uso de basiliximab en el tratamiento de artritis reumatoide o enfermedades de la piel.

Also Published As

Publication number Publication date
KR20020084107A (ko) 2002-11-04
US20050226872A1 (en) 2005-10-13
GB0007911D0 (en) 2000-05-17
CN1416432A (zh) 2003-05-07
NO20024579L (no) 2002-11-11
RU2286797C2 (ru) 2006-11-10
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
HUP0301846A3 (en) 2010-07-28
AU4651601A (en) 2001-10-08
KR20080079702A (ko) 2008-09-01
PL357014A1 (en) 2004-07-12
RU2002127800A (ru) 2004-03-27
BR0109549A (pt) 2003-06-10
US20090041775A1 (en) 2009-02-12
JP2003528890A (ja) 2003-09-30
SK13892002A3 (sk) 2003-05-02
ZA200207736B (en) 2003-05-08
WO2001072845A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
EP1268553A1 (en) 2003-01-02
HUP0301846A2 (hu) 2003-09-29
NO20024579D0 (no) 2002-09-24

Similar Documents

Publication Publication Date Title
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
HK1071769A1 (en) Therapeutic binding molecules
IL150628A0 (en) Use of lipid conjugates in the treatment of disease
EP1767544A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
EP1581119A4 (en) COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS FOR INFLAMMATORY BOWEL DISEASE
AP2002002690A0 (en) Antibody molecules having specificity for human tumor necrosis factor alphs and use thereof
AU7296801A (en) Il-17 molecules and uses thereof
IL173820A0 (en) Therapeutic binding molecules
IL181706A0 (en) The treatment of inflammatory disorders and pain
AU4651601A (en) Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
HK1067362A1 (en) Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract
AU2001287272A1 (en) Genes involved in intestinal inflammatory diseases and use thereof
EP1805210A4 (en) NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE
IL181240A0 (en) Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
TWI372060B (en) Nogo-a binding molecules and pharmaceutical use thereof
HUP0400986A3 (en) Use of cd25 binding molecules in steroid-resistant patients
GB0115780D0 (en) Therapeutic molecules and uses thereof
IL160310A0 (en) The use of anthroquinones in the treatment of kidney disease
HUP0302882A3 (en) Improved specificity in treatment of diseases
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
AU2728301A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
AUPQ549800A0 (en) Therapeutic and diagnostic molecules